<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629965</url>
  </required_header>
  <id_info>
    <org_study_id>1237.33</org_study_id>
    <nct_id>NCT02629965</nct_id>
  </id_info>
  <brief_title>Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients</brief_title>
  <official_title>A Randomised, Double-blinded, Active-controlled 2-way Cross Over Trial to Assess the Effects of 6 Weeks Treatment of Once Daily Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Delivered by RESPIMAT Inhaler Compared With Tiotropium Delivered by RESPIMAT Inhaler on Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a multi-centre, randomised, double-blinded, active-controlled, 2-way cross over trial
      to assess the effects of once daily administration of orally inhaled tiotropium + olodaterol
      FDC or tiotropium (both delivered by the RESPIMAT Inhaler) on pulmonary function (lung
      hyperinflation), exercise capacity (6-minute walk distance) and physical activities after 6
      weeks of treatment in Japanese patients with Chronic Obstructive Pulmonary Disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 12, 2016</start_date>
  <completion_date type="Actual">April 17, 2017</completion_date>
  <primary_completion_date type="Actual">March 24, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose</measure>
    <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
    <description>At day 43 inspiratory capacity at rest measured at 60 minutes post-dose, after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute Walk Distance [Meter]</measure>
    <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
    <description>6−minute walk distance [Meter] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Number of Step Per Day (Step/Day)</measure>
    <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of average number of step per day [step/day] treatment comparisons in measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Duration (Minutes) of ≥ 4 Metabolic Equivalents (METs)</measure>
    <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 4 METs treatment comparisons measured by the activity monitor in the 2 weeks prior to week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Duration (Minutes) of ≥ 3 Metabolic Equivalents (METs)</measure>
    <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Duration (Minutes) of ≥ 2 Metabolic Equivalents (METs)</measure>
    <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 2 METs treatment comparison measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily Active Strength (Metabolic Equivalents*Minutes) of ≥ 3 METs</measure>
    <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of average daily active strength [METs x minute] of &gt;=3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>60 Minutes Post-dose Slow Vital Capacity (SVC) (in Litre)</measure>
    <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of 60 minute post−dose slow vital capacity [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Minutes Post-dose Forced Expiratory Volume in One Second (FEV1) (in Litre)</measure>
    <time_frame>Day 43, 30 minutes post-dose after 6 weeks of each treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced expiratory volume in one second (FEV1) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Minutes Post-dose Forced Vital Capacity (FVC) (in Litre)</measure>
    <time_frame>Day 43, 30 minutes post-dose after 6 weeks of each treatment</time_frame>
    <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced vital capacity (FVC) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">184</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>tiotropium + olodaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium + olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium + olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <arm_group_label>tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  All patients must sign an informed consent consistent with International Conference on
             Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in
             the trial, which includes medication washout and restrictions.

          -  All patients must have a diagnosis of chronic obstructive pulmonary disease (COPD) and
             must meet the following spirometric criteria:

        Patients must have relatively stable airway obstruction with a post-bronchodilator Forced
        expiratory volume in one second (FEV1) &lt; 80% of predicted normal and post-bronchodilator
        FEV1/forced vital capacity (FVC) &lt; 70% at Visit 1.

          -  Male or female patients, aged &gt;= 40 years.

          -  Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years. Patients who have never smoked cigarettes must be excluded.

          -  Patients with score on the modified Medical Research Council (mMRC) &gt;= 1.

          -  Patients who walk &lt; 400 meters of 6MWT and have a score on the modified Borg &gt;= 4 at
             the end of 6 minute walk test (6MWT) at Visit 2.

          -  Patients must be able to perform technically acceptable pulmonary function tests
             (spirometry), to use the physical activity monitor and must be able to complete 6MWT
             during the study period as required in the protocol.

          -  Patients must be able to inhale medication in a competent manner from the RESPIMAT
             Inhaler and from a metered dose inhaler.

        Exclusion criteria:

          -  Patients with a significant disease other than COPD; a significant disease is defined
             as a disease which, in the opinion of the investigator, may put the patient at risk
             because of participation in the study, influence the results of the study and cause
             concern regarding the patient's ability to participate in the study.

          -  Patients with clinically relevant abnormal baseline haematology, blood
             chemistry,urinalysis or creatinine &gt; x2 upper limit of normal (ULN) will be excluded
             regardless of clinical condition (a repeat laboratory evaluation can be conducted if
             deemed necessary by the investigator).

          -  Patients with a current documented diagnosis of asthma. For patients with allergic
             rhinitis or atopy, source documentation is required to verify that the patient does
             not have asthma.

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiramatsu Internal and Respiratory Medicine Clinic</name>
      <address>
        <city>Aichi, Komaki</city>
        <zip>485-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Geriatric Medicine</name>
      <address>
        <city>Aichi, Obu</city>
        <zip>474-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Aichi, Seto</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nishi Fukuoka Hospital</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>819-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirigaoka Tsuda Hospital</name>
      <address>
        <city>Fukuoka, Kitakyushu</city>
        <zip>802-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaki Internal and Respiratory Clinic</name>
      <address>
        <city>Fukuoka, Kitakyushu</city>
        <zip>802-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohno Chuo Clinic</name>
      <address>
        <city>Gifu, Mizunami</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazda Hospital</name>
      <address>
        <city>Hiroshima, Aki-gun</city>
        <zip>735-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teine Keijinkai Clinic</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>006-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KKR Sapporo Medical Center</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>062-0931</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Hokkaido Hospital</name>
      <address>
        <city>Hokkaido, Sapporo</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Hyogo, Kobe</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Hospital Organization Kobe City Medical Center West Hospital</name>
      <address>
        <city>Hyogo, Kobe</city>
        <zip>653-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibarakihigashi National Hospial</name>
      <address>
        <city>Ibaraki, Naka-gun</city>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Iwate, Morioka</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakaide City Hospital</name>
      <address>
        <city>Kagawa, Sakaide</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Medical And Dental Hospital</name>
      <address>
        <city>Kagoshima, Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokan Clinic</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin-yurigaoka General Hospital</name>
      <address>
        <city>Kanagawa, Kawasaki</city>
        <zip>215-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Fujigaoka Hospital</name>
      <address>
        <city>Kanagawa, Yokohama</city>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rakuwakai Otowa Hospital</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uji-Tokushukai Medical Center</name>
      <address>
        <city>Kyoto, Uji</city>
        <zip>611-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsusaka City Hospital</name>
      <address>
        <city>Mie, Matsusaka</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi, Sendai</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku Rosai Hospital</name>
      <address>
        <city>Miyagi, Sendai</city>
        <zip>981-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada City Hospital</name>
      <address>
        <city>Osaka, Kishiwada</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka, Osakasayama</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka, Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama National Hospital</name>
      <address>
        <city>Osaka, Toyonaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yao Tokushukai General Hospital</name>
      <address>
        <city>Osaka, Yao</city>
        <zip>581-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Shimane, Izumo</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tenryu Hospital</name>
      <address>
        <city>Shizuoka, Hamamatsu</city>
        <zip>434-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo, Bunkyo-ku</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Respiratory Care Clinic, Nippon Medical School</name>
      <address>
        <city>Tokyo, Chiyoda-ku</city>
        <zip>102-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Sakura Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <zip>103-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hachioji Medical Center</name>
      <address>
        <city>Tokyo, Hachioji</city>
        <zip>193-0998</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo, Itabashi-ku</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo, Shinagawa-ku</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinjuku Research Park Clinic</name>
      <address>
        <city>Tokyo, Shinjuku-ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama National Hospital</name>
      <address>
        <city>Wakayama, Hidaka-gun</city>
        <zip>644-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>March 15, 2018</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 6, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02629965/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT02629965/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a randomised, double-blind, active-controlled, 2-way crossover trial to assess the effects of once daily treatment of orally inhaled Tiotropium + Olodaterol FDC 5 μg/5 μg or Tiotropium 5 μg over 12 weeks of treatment in Japanese patients with Chronic obstructive pulmonary disease (COPD).</recruitment_details>
      <pre_assignment_details>All patients were screened for eligibility to participate in the trial. Subjects attended specialist sites which would then ensure that all subjects met all inclusion/exclusion criteria. Subjects were not to be randomised to trial treatment if any one of the specific entry criteria were violated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium 5 μg / Tiotropium + Olodaterol 5/5 μg FDC</title>
          <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) in period 1 and Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) in period 2 once a day in the morning for a total of 12 weeks
2 treatments were not separated by wash-out periods.</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium + Olodaterol 5/5 μg FDC / Tiotropium 5 μg</title>
          <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) in period 1 and Tiotropium inhalation solution (2.5 microgram per actuation) in period 2 once a day in the morning for a total of 12 weeks.
2 treatments were not separated by wash-out periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unexpected worsening of disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than listed above</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): Treated set includes all particiapatns who took at least one study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>Total randomised participants in the trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The age data are presented by years.</description>
          <population>Treated set (TS): TS includes patients who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The sex data are presented by count of participants.</description>
          <population>Treated set (TS): TS includes patients who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>The race data are presented by count of participants. Ethnicity was not collected for this study.</description>
          <population>Treated set (TS): TS includes patients who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose</title>
        <description>At day 43 inspiratory capacity at rest measured at 60 minutes post-dose, after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity at Rest Measured at 60 Minutes Post-dose</title>
          <description>At day 43 inspiratory capacity at rest measured at 60 minutes post-dose, after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.875" spread="0.019"/>
                    <measurement group_id="O2" value="1.990" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>6-minute Walk Distance [Meter]</title>
        <description>6−minute walk distance [Meter] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>6-minute Walk Distance [Meter]</title>
          <description>6−minute walk distance [Meter] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Meter (m)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307.356" spread="5.170"/>
                    <measurement group_id="O2" value="311.524" spread="5.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4291</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.260</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.211</ci_lower_limit>
            <ci_upper_limit>14.548</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Step Per Day (Step/Day)</title>
        <description>At day 43 adjusted mean (SE) of average number of step per day [step/day] treatment comparisons in measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Step Per Day (Step/Day)</title>
          <description>At day 43 adjusted mean (SE) of average number of step per day [step/day] treatment comparisons in measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>step/day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3550.400" spread="93.123"/>
                    <measurement group_id="O2" value="3559.901" spread="93.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9098</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.501</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>83.704</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-155.692</ci_lower_limit>
            <ci_upper_limit>174.694</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Duration (Minutes) of ≥ 4 Metabolic Equivalents (METs)</title>
        <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 4 METs treatment comparisons measured by the activity monitor in the 2 weeks prior to week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Duration (Minutes) of ≥ 4 Metabolic Equivalents (METs)</title>
          <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 4 METs treatment comparisons measured by the activity monitor in the 2 weeks prior to week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.206" spread="0.497"/>
                    <measurement group_id="O2" value="9.914" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5338</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.292</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.469</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.217</ci_lower_limit>
            <ci_upper_limit>0.633</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Duration (Minutes) of ≥ 3 Metabolic Equivalents (METs)</title>
        <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Duration (Minutes) of ≥ 3 Metabolic Equivalents (METs)</title>
          <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.662" spread="0.979"/>
                    <measurement group_id="O2" value="45.601" spread="0.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3524</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.939</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.007</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.048</ci_lower_limit>
            <ci_upper_limit>2.926</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Duration (Minutes) of ≥ 2 Metabolic Equivalents (METs)</title>
        <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 2 METs treatment comparison measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Duration (Minutes) of ≥ 2 Metabolic Equivalents (METs)</title>
          <description>At day 43 adjusted mean (SE) of average daily duration [minute] of ≥ 2 METs treatment comparison measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.935" spread="2.506"/>
                    <measurement group_id="O2" value="174.192" spread="2.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3949</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.257</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.647</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.966</ci_lower_limit>
            <ci_upper_limit>7.481</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Daily Active Strength (Metabolic Equivalents*Minutes) of ≥ 3 METs</title>
        <description>At day 43 adjusted mean (SE) of average daily active strength [METs x minute] of &gt;=3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>2 weeks prior to Week 6 per treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Active Strength (Metabolic Equivalents*Minutes) of ≥ 3 METs</title>
          <description>At day 43 adjusted mean (SE) of average daily active strength [METs x minute] of &gt;=3 METs treatment comparisons measured by the activity monitor in 2 weeks prior to Week 6 of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Metabolic equivalents * minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.647" spread="3.723"/>
                    <measurement group_id="O2" value="151.067" spread="3.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4955</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.420</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.543</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.572</ci_lower_limit>
            <ci_upper_limit>9.411</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>60 Minutes Post-dose Slow Vital Capacity (SVC) (in Litre)</title>
        <description>At day 43 adjusted mean (SE) of 60 minute post−dose slow vital capacity [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>60 Minutes Post-dose Slow Vital Capacity (SVC) (in Litre)</title>
          <description>At day 43 adjusted mean (SE) of 60 minute post−dose slow vital capacity [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.962" spread="0.021"/>
                    <measurement group_id="O2" value="3.096" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.134</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Minutes Post-dose Forced Expiratory Volume in One Second (FEV1) (in Litre)</title>
        <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced expiratory volume in one second (FEV1) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 30 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Minutes Post-dose Forced Expiratory Volume in One Second (FEV1) (in Litre)</title>
          <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced expiratory volume in one second (FEV1) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.169" spread="0.011"/>
                    <measurement group_id="O2" value="1.275" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Minutes Post-dose Forced Vital Capacity (FVC) (in Litre)</title>
        <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced vital capacity (FVC) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 30 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Minutes Post-dose Forced Vital Capacity (FVC) (in Litre)</title>
          <description>At day 43 adjusted mean (SE) of 30 minute post−dose forced vital capacity (FVC) [Litre] treatment comparisons after 6 weeks of each treatment. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.857" spread="0.021"/>
                    <measurement group_id="O2" value="3.020" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Treatment Period</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Treatment Period</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.940" spread="0.022"/>
                    <measurement group_id="O2" value="2.072" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Baseline Period</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) Completer at Baseline Period</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.925" spread="0.021"/>
                    <measurement group_id="O2" value="2.053" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.100</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Test Comparisons of 6-Minute Walk Treatment (6MWT) in−Completer at Treatment Period</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT in−completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Test Comparisons of 6-Minute Walk Treatment (6MWT) in−Completer at Treatment Period</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each treatment for 6MWT in−completer at treatment period. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.738" spread="0.024"/>
                    <measurement group_id="O2" value="1.820" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) in−Completer at Baseline Period</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each test for 6MWT in−completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Treatment Comparisons of 6-Minute Walk Test (6MWT) in−Completer at Baseline Period</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] test comparisons after 6 weeks of each test for 6MWT in−completer at baseline period. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.744" spread="0.026"/>
                    <measurement group_id="O2" value="1.830" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage I/II</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage I/II. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage I/II</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage I/II. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.023" spread="0.023"/>
                    <measurement group_id="O2" value="2.106" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III/IV</title>
        <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage III/IV. Adjusted mean was entered instead of mean in statistical analysis.</description>
        <time_frame>Day 43, 60 minutes post-dose after 6 weeks of each treatment</time_frame>
        <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium 5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium inhalation solution (2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium + Olodaterol 5/5 μg</title>
            <description>Participants inhaled 2 puffs from the RESPIMAT Inhaler of the Tiotropium + Olodaterol inhalation solution (2.5/2.5 microgram per actuation) once a day in the morning for 2 periods for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Inspiratory Capacity [Litre] Treatment Comparisons of Subgroup of Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III/IV</title>
          <description>At day 43 adjusted mean (standard error) of inspiratory capacity [Litre] treatment comparisons after 6 weeks of each treatment for subgroup of GOLD stage III/IV. Adjusted mean was entered instead of mean in statistical analysis.</description>
          <population>Full analysis set (FAS): FAS includes participants who had baseline measurement and at least 1 post-baseline measurement for the primary endpoint or a secondary endpoint. The FAS was used for the efficacy analyses.</population>
          <units>Litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.697" spread="0.026"/>
                    <measurement group_id="O2" value="1.849" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Effect Model Repeated Measures includes treatment and period as fixed effects, study baseline as a covariate and patient as a random effect.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.189</ci_upper_limit>
            <estimate_desc>Adjusted mean of differences between treatments and standard error</estimate_desc>
            <other_analysis_desc>Mixed effect repeated measurement was used to calculate adjusted mean values as well as treatment contrasts together with the 95% confidence intervals (CIs) and p-values.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 12 weeks after last drug administration, up to 15 weeks</time_frame>
      <desc>An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation participants administered a trial medicine.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium 5</title>
          <description>Participants were orally inhaled 2 puffs from the RESPIMAT Inhaler with the Tiotropium fixed dose combination of 2.5 μg per actuation once a day in the morning for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium + Olodaterol 5/5</title>
          <description>Participants were orally inhaled 2 puffs from the RESPIMAT Inhaler with the Tiotropium + Olodaterol fixed dose combination of 2.5/2.5 μg per actuation once a day in the morning for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="182"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Centre</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

